Literature DB >> 31669915

Glucagon-like peptide-1 receptor expression and its functions are regulated by androgen.

Liying Zhu1, Jinxing Zhou2, Yu Pan3, Jing Lv4, Yang Liu5, Shanhe Yu6, Yifan Zhang7.   

Abstract

Glucagon-like peptide-1 receptor (GLP-1R) is an important pharmacological target for type 2 diabetes mellitus because it maintains glucose homeostasis and promotes β cell proliferation. Androgen is suggested not only to regulate hypothalamic-pituitary-gonadal axis but also to affect metabolism. In this study, Glp1r mRNA was found widely expressed in normal male mice and its levels were positively correlated with the serum testosterone (T) concentrations. Using mouse insulinoma 6 (MIN6) cells, which highly express GLP-1R, we observed GLP-1R was upregulated both at transcriptional and protein levels induced by dihydrotestosterone (DHT) and was downregulated by androgen receptor inhibitor ARN-509 or small interfering RNA (siRNA) targeting Glp1r mRNA. In normal C57BL/6 mice and db/db mice, Glp1r mRNA levels in the pancreases increased in the DHT treatment group and decreased in the ARN-509 treatment group. And the increased GLP-1R expression had insulinotropic function both in vitro and in vivo. Further analysis showed that the androgen receptor (Ar) located in the cytosol of MIN6 cells and translocated to the nucleus after DHT treatment. In addition, we found that there was an Ar motif in the promoter region of the Glp1r gene. Further studies revealed that the translocated DHT/Ar complex from the cytosol to the nucleus bound to the Ar motif of the Glp1r gene and upregulated gene transcription. Taken together, the widely expressed GLP-1R was positively regulated by androgen under physiological condition and in diabetic models at the transcriptional level.
Copyright © 2019 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  DHT/Ar; GLP-1R; Insulin; Type 2 diabetes mellitus

Mesh:

Substances:

Year:  2019        PMID: 31669915     DOI: 10.1016/j.biopha.2019.109555

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  4 in total

Review 1.  Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence.

Authors:  Radica Z Alicic; Emily J Cox; Joshua J Neumiller; Katherine R Tuttle
Journal:  Nat Rev Nephrol       Date:  2020-11-20       Impact factor: 28.314

2.  Remission of type 2 diabetes following long-term treatment with injectable testosterone undecanoate in patients with hypogonadism and type 2 diabetes: 11-year data from a real-world registry study.

Authors:  Karim Sultan Haider; Ahmad Haider; Farid Saad; Gheorghe Doros; Markolf Hanefeld; Sandeep Dhindsa; Paresh Dandona; Abdulmaged Traish
Journal:  Diabetes Obes Metab       Date:  2020-07-15       Impact factor: 6.577

3.  Icariin Ameliorates Diabetic Renal Tubulointerstitial Fibrosis by Restoring Autophagy via Regulation of the miR-192-5p/GLP-1R Pathway.

Authors:  Zhirong Jia; Kaiwei Wang; Yameng Zhang; Yalei Duan; Kang Xiao; Shuo Liu; Xuansheng Ding
Journal:  Front Pharmacol       Date:  2021-07-19       Impact factor: 5.810

Review 4.  Sex differences feed into nuclear receptor signaling along the digestive tract.

Authors:  Angela E Dean; François Reichardt; Sayeepriyadarshini Anakk
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2021-07-14       Impact factor: 5.187

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.